DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Thalassemia — screening already-approved drugs against its 21-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleThalassemia maps to a 21-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for thalassemia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
hemoglobin subunit beta (HBB) — HBB is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet hemdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1DXT · 1.7 Å · ligand PROTOPORPHYRIN IX CONTAINING FE (HEM). Experimental structure, not a prediction.
What the evidence adds up to
Thalidomide was tested in seven patients with thalassemia intermedia who required blood transfusion. Four of these patients were transfusion-independent before treatment, and three were transfusion-dependent. Among the four transfusion-independent patients, haemoglobin concentration increased by at least 2 g/dl in three and by 1 to 2 g/dl in one. After three months of treatment, the average haemoglobin increase across these four patients was 3.2 ± 1.2 g/dl compared to before treatment. Among the three transfusion-dependent patients, one stopped needing transfusions after one month of treatment, and the other two reduced their transfusion requirement by more than 50%, with an accompanying rise in average haemoglobin concentration. The authors concluded that thalidomide had a significant effect in this small group and called for larger, more rigorous studies.
The molecular basis of thalassemia is diverse. Gene deletions, nuclear RNA processing defects, nonsense mutations, fusion genes, termination codon mutants, and unstable globin chains have all been identified as causes of the thalassemia phenotype. In alpha-thalassemia, deletions of one or two alpha-globin genes are the primary cause. In a screening study of 173 healthy volunteers in Yogyakarta, Indonesia, the most common deletions were the South-East Asia (SEA) deletion, the 3.7-kb deletion, and the 4.2-kb deletion. Haematological parameters showed that mean corpuscular volume (MCV) and mean corpuscular haemoglobin (MCH) were significantly lower in carriers of alpha-thalassemia trait than in normal individuals, and MCH was the more reliable parameter for identifying the number of defective genes.
Patients with thalassemia major suffer from many complications, but their lives have improved in both length and quality over the last two decades. New therapeutic strategies have been introduced into practice, and others are still being developed. The 1982 review notes that the causes of the thalassemia phenotype are now understood to be diverse, but no treatment data from that paper are available.
What is still missing is a larger, more rigorous trial of thalidomide in thalassemia intermedia, with more patients and a controlled design. The molecular and haematological data from Indonesia come from a screening study, not a treatment trial. No randomised controlled trial data exist for any drug in these abstracts, and no information on long-term safety or patient stratification by genotype is provided.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Hematology · 2017 · 26 citations · open access
Thalidomide has a significant effect in patients with thalassemia intermedia
AbstractOBJECTIVE: To investigate the effect of thalidomide in patients with thalassemia intermedia. METHODS: We observed the effect of thalidomide in seven patients with thalassemia intermedia requiring blood transfusion. Four of the patients were transfusion-independent, and three patients were transfusion-dependent. RESULTS: For the four transfusion-independent patients, hemoglobin concentration increased significantly (≥2 g/dl) in three and moderately (1-2 g/dl) in one. After 3 months of treatment, hemoglobin concentration increased 3.2 ± 1.2 g/dl compared to pretreatment. Among the three transfusion-dependent patients, transfusion was terminated after one month of treatment in one patient and decreased >50% in the other two patients, accompanied by an increase in the average hemoglobin concentration. CONCLUSION: Thalidomide had a significant effect in patients with thalassemia intermedia. Further studies of a larger scale and more rigorous design are warranted.
American Journal of Hematology · 1982 · 14 citations
Thalassemia: Recent insights into molecular mechanisms
AbstractRecent advances in defining the molecular basis for the thalassemia syndromes are discussed. We now realize that the causes of the thalassemia phenotype are diverse and include gene deletions, nuclear RNA processing defects, nonsense mutations, fusion genes, termination codon mutants, and unstable globin chains.
A complicated disease: what can be done to manage thalassemia major more effectively?
AbstractPatients with thalassemia major suffer from many complications, but in the last two decades their lives have improved both in length and quality. We report herein the most common complications and the recent advances that have changed the course of this disease. Also, we report in detail some of the new therapeutic strategies already introduced in practice and briefly some that are still being developed.
Reports of Biochemistry and Molecular Biology · 2021 · 8 citations · open access
Molecular and Haematological Characteristics of alpha-Thalassemia Deletions in Yogyakarta Special Region, Indonesia
AbstractBACKGROUND: alpha-Thalassemia is caused primarily by deletions of one to two alpha-globin genes and is characterized by absent or deficient production of alpha-globin protein. The South-East Asia (SEA) deletion, 3.7-kb and 4.2-kb deletions are the most common causes. The present study aimed to observe the molecular characteristics of this common alpha-Thalassemia deletions and analyse its haematological parameter. METHODS: Blood samples from 173 healthy volunteers from thalassemia carrier screening in Yogyakarta Special Region were used. Haematological parameters were analysed and used to predict the carrier subjects. Genotype of suspected carriers was determined using multiplex gap-polymerase chain reaction and its haematological parameters were compared. The boundary site of each deletion was determined by analysing the DNA sequences. RESULTS: /αα (29.4%). The 5' and 3' breakpoints of SEA deletion were located at nt165396 and nt184700 of chromosome 16, respectively. The breakpoint regions of 3.7-kb deletion were 176-bp long, whereas for 4.2-kb deletion were 321-bp long. The haematological comparison between normal and those with alpha-Thalassemia trait genotype indicated a significant difference in mean corpuscular volume (MCV) (p< 0.001) and mean corpuscular haemoglobin (MCH) (p< 0.001). As for identifying the number of defective genes, MCH parameter was more reliable (p= 0.003). CONCLUSION: The resultant molecular and haematological features provide insight and direction for future thalassemia screening program in the region.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
